5,931 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,931 shares of the biotechnology company's stock, valued at approximately $886,000.

Several other large investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in shares of Ascendis Pharma A/S by 221.0% in the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock worth $833,000 after buying an additional 4,205 shares during the period. Legato Capital Management LLC lifted its stake in Ascendis Pharma A/S by 167.6% in the second quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company's stock worth $590,000 after acquiring an additional 2,708 shares during the period. Searle & CO. purchased a new stake in Ascendis Pharma A/S in the second quarter worth about $205,000. Rhumbline Advisers grew its holdings in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after acquiring an additional 143 shares in the last quarter. Finally, Candriam S.C.A. increased its position in Ascendis Pharma A/S by 96.6% during the 2nd quarter. Candriam S.C.A. now owns 195,347 shares of the biotechnology company's stock valued at $26,640,000 after purchasing an additional 95,972 shares during the period.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $0.77 during trading on Friday, hitting $129.87. The company's stock had a trading volume of 239,491 shares, compared to its average volume of 448,612. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The business's 50 day simple moving average is $129.41 and its 200-day simple moving average is $132.69.

Analyst Ratings Changes

ASND has been the subject of several research reports. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. Wedbush reissued an "outperform" rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.